Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt

Oncogenic DHX15 mutation enhances mitochondrial metabolism and sustains leukemia stemness.

Qi-Long Li Pei-Qi Xing Jin Xu Jifei Li Liang-Jie Chen Xinlu Li Yin-Peng Bai Gang Li Ting Xie Lu-Zheng Wang Yuan Wang G. Qing Hua-Feng Wang Liang Shao Wei Wu Zhaoqi Liu Hudan Liu
Aug 2026 · Leukemia · 0 citations · 42 references
Medicine

TL;DR

Functional analysis demonstrates that DHX15R222G cooperates with AML1-ETO fusion protein to enhance AML leukemia stem cell (LSC) activity and promote resistance to standard chemotherapy, and underscores the pivotal role of oncogenic DHX15 mutations in regulating AML LSC activity.

DOI PubMed Semantic Scholar
View source

Similar papers

Aug 2026

ARID1B mutations promote immune evasion in acute myeloid leukemia through upregulating VISTA expression.

Acute myeloid leukemia (AML) is defined by epigenetic heterogeneity, and recurrent mutations in chromatin remodelers are associated with a poor prognosis. Whether these mutations drive treatment resistance through remodeling of the tumor immune microenvironment remains unclear. ARID1B, a recurrently mutated SWI/SNF sub...

Wan-Xiu Mao, Jia-Yi Cui, Hanqi Su et al. · 0 citations
Open access Sep 2026

AML1-ETO hijacks a distal enhancer of NAT10 to reprogram glutathione metabolism and sustain leukemia stem cell stemness.

Chromosomal translocations produce oncogenic fusion proteins such as AML1-ETO, which predominantly occupy gene promoters to induce transcriptional reprogramming in leukemia stem cells (LSCs), consequently driving the pathogenesis of t(8;21) acute myeloid leukemia (AML). However, whether AML1-ETO is recruited to additio...

Shuyi Li, Shu-Jiao He, Yongwei Su et al. · 0 citations
Open access Aug 2026

A PTBP1–CDC42 splicing axis regulates leukemia growth and venetoclax sensitivity in acute myeloid leukemia

PTBP1 is established as a critical regulator of AML cell fitness and a clinically actionable therapeutic combination that exploits AML dependency on PTBP1-CDC42 signaling to enhance the efficacy of venetoclax-based regimens is identified.

Margaux Oberling, Mathieu Landry, Yann Aubert et al. · 0 citations
Open access Sep 2026

Transcription factor 12 promotes acute myeloid leukemia cell survival by regulating mitochondrial function and ROS.

Acute myeloid leukemia (AML) cells rely heavily on mitochondrial oxidative phosphorylation (OXPHOS) for energy, making mitochondrial function a promising therapeutic target. TCF12, a transcription factor belonging to the basic helix-loop-helix (bHLH) family, has been implicated in various cancers and is highly expresse...

Nian-Xue Wang, Jian-Hong Xie, Ru-Ya Zhang et al. · 0 citations
Aug 2026

Dual MYC and GSPT1 Protein Degrader for MYC-Driven Hematologic Malignancies.

The data support the development of the MYC/GSPT1 degrader GT19630 as a therapeutic strategy of MYC-driven hematologic malignancies as a therapeutic strategy of therapy-resistant hematologic malignancies.

Yuki Nishida, Valeria Impedovo, Edward Ayoub et al. · 0 citations
Review Open access 2026

Transcriptional Control as a Therapeutic Strategy in Acute Myeloid Leukemia

: Acute myeloid leukemia (AML) is driven by dysregulated transcription factors (TFs) that disrupt hematopoietic differentiation, promote leukemic self-renewal, and confer therapy resistance. Key TFs including C/EBP α , PU.1, RUNX1, GATA2, EVI1, PML-RAR α fusion protein, p53, c-Myc and ERG are altered through mutations,...

Annisa Nurul Ilmi, Rudy Agung Nugroho, Sendy Junedi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.